abstract |
Dosage regimens of anti-α-synuclein antibodies are provided. Such dosing regimens include Synuclein disease such as Parkinson's disease (PD), Parkinson's dementia (PDD), Lewy body dementia (DLB), Alzheimer's disease of Lewy body variants (LBVAD), pure autonomic dysfunction (PAF), multisystem atrophy (MSA), and use in the treatment of neurodegeneration (NBIA-I) with brain iron accumulation type-1. |